Newer Nicotine and Tobacco Products: British American Tobacco

This page was last edited on at

Since the early 2000s transnational tobacco companies (TTCs) have developed interests in newer nicotine and tobacco products, including e-cigarettes (also known as electronic delivery systems, or ENDS), heated tobacco products (HTPs), snus and nicotine pouches.

Companies have referred to these types of product as ‘next generation products’ (NGPs) although terminology changes over time.

As the harms from conventional products have become better understood, and tobacco control measures have been put in place, the cigarette market – from which tobacco companies make most of their profits – has started to shrink. To secure the industry’s longer-term future, TTCs have invested in, developed and marketed various newer products, including in low and middle-income countries.1  They are often publicly linked to tobacco companies’ harm reduction strategies and labelled ‘reduced risk’ or ‘modified risk’ products.

There is ongoing scientific and policy debate about the role of these products in tobacco control, with concerns around long term health effects, marketing to youth, and how this diversification may help the industry to build credibility and influence  policy makers.12

It is important to note that, despite increasing investment in these products, the core of the global tobacco industry’s business remains unchanged. Newer products form a small proportion of their revenue, compared to conventional products, and will do so for the foreseeable future.


Like its competitors, British American Tobacco (BAT) has been investing in newer nicotine and tobacco products that, unlike cigarettes, have potential for growth in developed markets. 3 BAT’s NGPs include snus, nicotine pouches, e-cigarettes, and heated tobacco products (HTPs).

BAT has promoted its investment in newer products under the phrase “transforming tobacco” and the slogan “creating a better tomorrow”, stating that these investments are a testimony to the company’s commitment to offer “…an unrivalled suite of potentially reduced-risk products that address the varied preferences of today’s consumers”.456

In 2018, BAT stated that it had invested more than US$1 billion since 2012 in “building a whole new area of the business focused exclusively on Next Generation Products”.7 The company added: “These new products offer us another opportunity to further grow our business, while also having the potential to reduce smoking-related disease because they are considered to be less risky than normal cigarettes”.7

Yet the company’s 2018 annual report indicated that cigarettes remain at the heart of the company’s business:

“As we develop new and potentially reduced-risk product categories, our conventional cigarette business remains strong and continues to grow. This enables us to invest in the development of better and more innovative products, while continuing to deliver strong results and dividends to our shareholders.”5

This is particularly true for low and middle-income countries (LMICs). In 2020, during the COVID-19 pandemic, BAT reported that volume of its sales of cigarettes and other conventional tobacco products grew in Brazil, Bangladesh and Turkey, while, according to BAT, sales in  developed markets remained “resilient”.8 In June 2021, BAT reassured investors that it had a profitable business “able to drive value from Combustibles” which remained key to growing its revenue.9


Snus is a smokeless tobacco product, traditional to Sweden, and is sold as a paste or in a tiny pouch that is placed between the gum and upper lip for a period of time.

Lyft nicotine pouch container
Image 1: BAT’s tobacco-free snus Lyft (screenshot from, November 2019)

In 2005 BAT started its snus activities with limited trial markets in South Africa, Scandinavia, Canada, and Japan.10

Three years later the company acquired Swedish snus manufacturer Fiedler & Lundgren.11

In 2011, BAT “scaled back” its snus activities to Scandinavia only, “to review our [BAT’s] approach to developing new reduced risk product categories”.12

However, in 2017 BAT’s snus activity once again picked up. Following its acquisition of Reynolds American Inc. (RAI) in the United States (US), the company gained ownership of Camel snus in the US. In Europe, that same year, BAT acquired Swedish snus company Winnington AB, adding Epok to its portfolio.1314

Nicotine pouches

In late 2018, BAT introduced snus-style nicotine pouches (which do not contain tobacco leaf) to its portfolio, marketing them as Lyft in the United Kingdom (UK) and Sweden (see image 1), and Velo in the US.151617 Media reports and the company’s social media posts indicate that these nicotine pouches were being promoted in lower and middle-income countries, including Ukraine,18 Belarus,19 Kazakhstan,20 Tanzania,2122 and Kenya.212324

In 2019, BAT started reframing its language around its pouch products, creating a distinction between its older tobacco leaf brands and new brands like Epok. Up to March 2021 it referred to both Epok white tobacco snus and nicotine pouches as “modern oral products”.25 After this, Epok was no longer mentioned on BAT’s main website.26

A BAT presentation from March 2019 pointed to a potential global market for these products: the “large existing base of oral products consumers around the world”.27 While describing its nicotine pouch market share in Russia, in December 2019, BAT finance director, Tadeu Marroco, also said that “Everything is doing well in Russia. We have a strong portfolio of combustibles there”.28 Once again BAT’s statements underline the continuing importance of conventional tobacco products to its business.

In August 2020, BAT (Reynolds) rebranded its nicotine lozenge Revel as VELO and stated that it had submitted it to the US Food and Drug Administration (FDA) for pre-market approval.293031 As of 2023, BAT stated it still awaited the FDA’s decision, but VELO was available in 34 other markets.32


Image 2: Selection of BAT’s Vype e-cigarettes (screenshot taken from, November 2019)

After its snus acquisitions, BAT briefly dabbled in a regulatory-approved nicotine inhaler, and then turned its focus on e-cigarettes.33

  • Read more about what an e-cigarette is here.

Invested in Licensed Medical Products

In 2010 BAT set up a company called Nicoventures to focus entirely on the “development and commercialisation of regulatory-approved [TobaccoTactics emphasis] nicotine products”.34 The company’s media release said that this move was a “natural extension of British American Tobacco’s approach to tobacco harm reduction…”35 Soon after, Nicoventures entered into a distribution agreement with entrepreneurial healthcare company Kind Consumer Limited to commercialise the latter’s non-electronic nicotine inhaler, Voke. After a lengthy application process the product was licensed as a medicine. For details see Kind Consumer

However, in early 2017 BAT pulled out of the partnership. BAT’s Scientific Director David O’Reilly conceded that BAT was never fully committed to ensuring that its products were compliant with medical grade safety standards:

“We were never really interested in prescription products. At that time, the medicinal route was the only route to market, but smokers do not see themselves as patients. Now there are additional routes to market, and we are devoting significant time and resources to extending consumer choice and delivering even better next-generation tobacco and nicotine products”.36

One of the so-called “additional routes to market” referred to by O’Reilly was e-cigarettes.

Acquired and Developed E-cigarettes

BAT was one of the first tobacco companies to enter the e-cigarette market (after RJ Reynolds and Altria, see: E-cigarettes: Industry Timeline) with the launch of its Vype e-cigarette on the UK market on 30 July 2013.37 The e-cigarette was developed by a company called CN Creative, which had been acquired by BAT the year before.3839 

From 2015 to 2019, BAT bought several other small e-cigarette manufacturers (CHIC, Ten Motives, VIP, and Twisp), and in 2017 inherited the popular Vuse e-cigarette when it acquired tobacco conglomerate Reynolds American Inc. (RAI). In 2019, BAT/Reynolds acquired a share of e-liquid manufacturer VapeWild, although it was subsequently closed down.8 In January the same year BAT also acquired a minority share of Ayr Ltd, a UK manufacturer and retailer.40

Vype and Vuse were BAT’s flagship brands, both marketed in various formats (see image 2 for Vype brand extensions). BAT began consolidating its e-cigarettes under one global brand, Vuse.3341 See below for more details.

To date, the e-cigarette is BAT’s most widely sold newer product, albeit not with the biggest profit margin (see below).33 “Key markets” for BAT were initially the UK, France, Germany, Canada and Mexico (where it launched in February 2019).42 It added the US to this list in 2020.8 In addition, BAT has sold its e-cigarettes in the US, Guatemala, Colombia, Germany, Ireland, Poland, Hungary, Kuwait, Bahrain, Greece, Italy and New Zealand.434445 As of 2023, Vuse is available in 63 markets, with the US, UK, France, Germany and Canada being the top 5.32

Read more detailed information on BAT’s e-cigarettes business here:

See also Cannabis below.

Launched ‘Vape Explained’ website

In December 2020, BAT launched a website This was described as “a digital information hub providing adult smokers and vapers with factual answers to the questions most commonly searched for online.”47

BAT stated that the site would help people make informed decisions and “separate fact from fiction”, and that it was “not operated for advertising or marketing purposes”.48

In February 2022, the company was promoting a similar site it had set up in Canada, called

Heated Tobacco Products

An image of BAT's glo devices

Image 3: Selection of BAT’s glo HTP devices (screenshot taken from, November 2019)

Due to its focus on e-cigarettes, BAT entered the HTP market later than its competitors Philip Morris International (PMI) and Japan Tobacco International (JTI).

BAT’s flagship heated tobacco product (HTP) is glo which uses neo tobacco sticks (called Neostiks). It was first launched in Japan in 2016, which remains one of its key markets. As of 2023, glo is available in 31 markets, the largest of which are countries in Asia and Europe.32

In October 2023, BAT announced that it had launched a new non-tobacco nicotine infused stick for glo, called veo, apparently to circumvent tobacco flavour bans.505152

In February 2024, Italy’s competition authority fined BAT €6 million (US$6.4 million) for misleading advertising relating to BAT’s HTPs.53

In 2024, BAT reached a settlement with PMI in a patent dispute relating to its HTPs and e-cigarettes.54 For details see Heated Tobacco Products.


In February 2020, BAT announced that they were researching CBD and THC flavourings for their e-cigarettes.55 In January 2021 BAT said that it had begun test sales of a CBD products called the “VUSE CBD Zone in Manchester, UK, with a potential roll-out later in 2021.56 BAT’s 2023 annual report indicated continued interest in CBD and cannabis, including establishing a “Centre of Excellence” to develop “the next generation of cannabis products” and investments in existing companies with established CBD, medical cannabis and hemp extract products.32

Changed Risk Statements

BAT has reframed the language and health claims it has made for its newer products over time. In 2014, BAT stated on its website that smoking its e-cigarettes was “substantially less risky than smoking tobacco”.57 By April 2016 it had started to refer to its e-cigarettes as “vapour products” which, along with its HTPs, it now deemed “less risky alternatives” to conventional cigarettes. 58 By mid-2018, BAT had begun using the term “Potentially Reduced Risk Products” (PRRPs).5445960 It defined these in 2019 as products which:

“have been shown to be reduced-risk; are likely to be reduced-risk; or may have the potential to be reduced-risk, in each case if switched to exclusively as compared to continuing to smoke cigarettes.”61

A disclaimer adds that no such claims are made in the US without clearance from the Food and Drug Administration, the FDA.61 However in 2021, BAT dropped the word “potentially”, and referred to these products as “reduced-risk products”, citing “the weight of evidence and assuming a complete switch from cigarette smoking”, in addition to the US disclaimer.6263

NGPs: An “Additive” Opportunity for BAT?

Image 4: BAT tells investors that nicotine users are a growth market.44

Irrespective of the product or claims of harm reduction motives, BAT’s primary goal remains the same: growing its market share and revenue in order to deliver profits and returns to shareholders.

Global Nicotine Market Growing?

At the company’s Investor Day in March 2019, BAT’s Chief Marketing Officer Kingsley Wheaton reported that BAT estimates showed that the number of tobacco and nicotine consumers had grown since 2013.6 A few months earlier, in October 2018, BAT’s then-CEO Nicandro Durante had hosted a briefing session for industry analysts, sharing BAT data that showed an increase in nicotine users from 345 million in 2012 to 362 million in 2017 in its markets outside the US (see image 4).44 The increase reversed a decline in nicotine use from 2007, as people gave up smoking cigarettes, indicating that newer products were at least partially responsible for the growth in the number of people in the “nicotine consumer pool” since then.

New “Entrants”

Image 5: At its 2019 Investor Day, BAT showed investors that “new entrants” make up a “significant portion” of the growth in users of newer products.(Source: British American Tobacco website)

At the 2019 BAT Investor Day, BAT’s Director New Categories, Paul Lageweg, showed investors that BAT “was back in the growth business” and that category growth was “driven by entrants”.64 BAT defined “entrants” as people aged 18 and older who are entering the “nicotine category”,64 in other words, those who previously did not smoke or use other nicotine products such as e-cigarettes or snus. According to Lageweg, three million new nicotine users entered these “new categories” globally in 2018.64 The share of new entrants was particularly high in the US.64 This may have been due to the popularity of a product of one of its competitors, JUUL Labs, amongst US teenagers.

Of the various products in the NGP category, Lageweg suggested that a higher proportion of increased sales of e-cigarettes (58%) could be attributed to new entrants, compared to the proportion for HTPs (11%) (see image 5).64 Lageweg added that although growth in HTPs was driven by switchers (those that switch from smoking cigarettes), its proportion of new entrants was still growing. According to Lageweg, 50% of the increase in the snus market was due to new nicotine users.64

Dual Use and “New Consumption Moments”

Image 6: BAT showing investors at its 2019 Investor Day how poly-use leads to ‘moments being regained’64

Emerging industry evidence suggest that a significant number of smokers may not be necessarily switching to newer nicotine and tobacco products, but use these products alongside cigarettes (known as dual, or poly use).

In a presentation to investors in September 2019, CEO Jack Bowles and Finance Director Tadeu Marroco reported “evidence of poly-usage across the categories”.42 In his March 2019 presentation, Lageweg had been more specific and showed investors a graph that suggested that 65% of e-cigarette users were dual users, as opposed to 55% of HTP users.64 The year before, then-CEO Durante said that dual use had become “the key consumer dynamic”, with dual use growing from 13% to 23% in less than one year.44 In its 2021 annual report, BAT stated its own research suggested “a high percentage of modern oral users are already poly-users of other categories”.65

BAT has also told investors that due to dual use, “moments are being regained” (see image 6).64 By that, the company means that smokers now have other products to use when smoking is not allowed or socially unacceptable, such as in a shared office, at home with family, or in public social spaces. Another BAT presentation identified the most popular “new occasions” for e-cigarette users were “when I can’t smoke cigarettes” (86%), “In the car” (62%) and “Inside pubs and restaurants”(47%).44

Expectations Going Up in Smoke?

Like its competitors, BAT has been ambitious in setting targets for its newer nicotine and tobacco products.

In 2019, the company said that it was going to double its revenue from these products by 2023/24 to UK£5 billion.33 It also claimed that this part of the business was more profitable than cigarettes, which had a 65% profit margin. HTPs were described as the most profitable (81%), with double the profit margin of e-cigarettes (42%). Snus was also more profitable (78%), while the newer nicotine pouches were less so (66%).6 However the profit margin on HTPs had fallen by 2% the previous year, while it had increased on every other product, with the margin on e-cigarettes nearly doubling.6 

In September 2019 the company announced that it was going to cut 2,300 jobs globally, allegedly so that it could continue to invest in its newer products.66 One month later, the company appeared to be lowering investor expectations regarding sales.67 In late November 2019, BAT announced that it was “simplifying” its portfolio to focus on three flagship brands only: e-cigarettes would be branded as Vuse, “modern oral” products as Velo, and HTPs as glo.68 As of 2021, this rebranding was ongoing.869

In its 2020 and 2021 annual reports, BAT reiterated the UK£5 billion goal, through a “step change in New Categories”, but with the target year pushed back to 2025.865 In 2021 BAT told investors that its “new category” products were still on a “pathway to profitability”.970

Rebranded Using New Products Slogan

In March, 2020 BAT rebranded its website, with a new logo and the prominent strapline ‘A Better Tomorrow’, placing the slogan at the centre of BAT’s strategy7172 However, tobacco products remain “at the core” of its business and key to growth, while “Stimulating the Senses of New Adult Generations” with products across all its ranges.72

In 2021, BAT claimed “15 million users of our non-combustible products” (which would include snus and heated tobacco) and that it aimed to reach 50 million by 2030.970 It did not specify how many of those consumers are in LMICs, but BAT noted that its target  markets vary according to consumer preference and regulatory restrictions:9

“If you think about New Categories, generally they are working in the sort of northern hemisphere markets on a sort of swath from America, through Canada, West Europe that’s the sort of Vapour heartland. Then through into Southern and Central Europe and the CIS and Northern Asia, where it becomes progressively more tobacco heating.”

There are also demographic differences which impact on the markets BAT chooses to target. For example, in Canada there is much higher proportion of teenage and young adult customers (many of whom have never smoked) compared to the UK, where more customers are older and former smokers.73 (Note that the picture has since changed with the rising popularity of single-use products, in which TTCs, including BAT, have invested and increasing concerns around youth use in the UK and other countries) Differing regulation, including country-specific rules governing nicotine levels and flavours, is also a factor.7374 According to the NGO Physicians for a Smoke-Free Canada, BAT sells the most high-nicotine products there.74 See the main page on E-cigarettes for more information on this topic.


See the page on Harm Reduction for an explanation of how the tobacco industry makes use of the language of public health to advance its commercial objectives.

BAT is one among several tobacco companies that have invested in therapeutic products such as nicotine lozenges, gum and inhalers. More information can be found on this page:

TobaccoTactics Resources

Relevant links

TCRG Research

Tobacco industry messaging around harm: Narrative framing in PMI and BAT press releases and annual reports 2011 to 2021, I. Fitzpatrick, S. Dance, K. Silver, M. Violini, T.R. Hird, Frontiers in Public Health, 18 October 2022, doi:10.3389/fpubh.2022.958354

Transnational tobacco company interests in smokeless tobacco in Europe: Analysis of internal industry documents and contemporary industry materials, S. Peeters, A. Gilmore, PLoS Medicine, 2013,10(9):1001506

Understanding the emergence of the tobacco industry’s use of the term tobacco harm reduction in order to inform public health policy, S. Peeters, A.B. Gilmore, Tobacco Control, 2015; 24:182-189, doi:10.1136/tobaccocontrol-2013-051502

For a comprehensive list of all TCRG publications, including TCRG research that evaluates the impact of public health policy, go to the Bath TCRG’s list of publications.

Print Friendly, PDF & Email


  1. abSTOP, Addiction At Any Cost: The Truth About Philip Morris International, 20 February 2020, accessed January 2021
  2. S. Peeters, A.B. Gilmore, Understanding the emergence of the tobacco industry’s use of the term harm reduction in order to inform public health policy, Tobacco Control, 2015; 24:182-189, doi:10.1136/tobaccocontrol-2013-051502
  3. Euromonitor International, Global Tobacco Key Findings Part 2: Vapour Products. August 2016 (behind paywall)
  4. British American Tobacco, British American Tobacco underlines commitment to transforming in latest Group reports, News Release, BAT website, 15 March 2018, accessed November 2019
  5. abcBritish American Tobacco, Transforming Tobacco. Annual Report and Form 20-F 2018, BAT website, accessed November 2019
  6. abcdK. Wheaton, Accelerating Growth in the New Nicotine World, British American Tobacco Investor Day presentation, BAT website, 14 March 2019, accessed November 2019
  7. abBritish American Tobacco, Our Next Generation Products business, BAT website, undated, accessed February 2018
  8. abcdeBritish American Tobacco, Building the Enterprise of the Future: Annual Report and Form 20-F 2020, April 2020
  9. abcdBritish American Tobacco, Deutsche Bank Global Consumer Conference, Q&A transcript, 9 June 2021, accessed August 2021
  10. British American Tobacco, Smokeless snus to be pioneered in Canada, News Release, 13 September 2007
  11. S. Peeters, A. Gilmore, Transnational tobacco company interests in smokeless tobacco in Europe: Analysis of internal industry documents and contemporary industry materials, PLoS Medicine, 2013,10(9):1001506
  12. British American Tobacco, Sustainable Growth: Sustainability Summary 2010, BAT website, March 2011, accessed February 2020
  13. British American Tobacco’s acquisition of Swedish snus maker Winnington Holding AB, Global Legal Chronicle, 23 January 2017, accessed November 2019
  14. L. Waters, Why did BAT kill the EPOK brand for LYFT?, SnusCENTRAL, 18 March 2019, accessed November 2019
  15. British American Tobacco, Oral tobacco and nicotine products, BAT website, undated, archived 11 January 2019, accessed November 2019
  16. C. Gretler, Grandad’s Tobacco Gets a Makeover, Bloomberg, 23 August 2019, accessed November 2019
  17. British American Tobacco sets the pace in Potentially Reduced Risk Products, Grocery Trader, 31 March 2019, accessed November 2019
  18. velo_pouches_ua,Ukraine Instagram account, accessed February 2020
  19. velo_pouches_by, Belarus Instagram account, accessed February 2020
  20. velo_pouches_kz, Kazakhstan Instagram account, accessed February 2020
  21. abCapital FM, Kenya: BAT to Launch Smoke-Free Cigarettes in Kenya,, 19 July 2019, accessed November 2019
  22. M. McGrady, African Experts Explain Their Challenges in Reducing Tobacco Harms, Filter Mag, 29 July 2019, accessed December 2019
  23. T. Rajula, Explainers: All about nicotine pouches, Daily Nation, 4 December 2019, accessed December 2019
  24. J. Otieno, All eyes on Health ministry over control of tobacco use, Standard Digital, 15 December 2019, accessed December 2019
  25. British American Tobacco, Modern and traditional oral products, BAT website, archived 2 March 2021, accessed July 2020
  26. British American Tobacco, Modern and traditional oral products, BAT website, archived 30 March 2021, accessed July 2020
  27. V. Duhem, Oral Category, The New Opportunity, British American Tobacco Investor Day, BAT website, 14 March 2019, accessed November 2019
  28. British American Tobacco, 2019 Second Half Pre-Close Trading Update, Conference call transcript, 27 November 2019, accessed February 2020
  29. Reynolds Submits First VELO Dissolvable Nicotine Lozenge Premarket Tobacco Product Applications, PR Newswire, 24 August 2020, accessed August 2020
  30. Reynolds Submits First Velo PMTA, Tobacco Reporter, 24 August 2020, accessed August 2020
  31. E. Brodwin, Tobacco giant Reynolds just rolled out berry and cream nicotine lozenges as it faces new pressure from Juul for smokeless products, Business Insider, 27 March 2019, accessed August 2020
  32. abcdBritish American Tobacco, 2023 Combined Annual and Sustainability Report, Annual Report, 2023, Available from
  33. abcdJ. Bowles, Paris DB Consumer Conference 12 June 2019, British American Tobacco website, accessed November 2019
  34. C. Cookson, BAT aims to smoke out nicotine lovers who find cigarettes a drag, Financial Times, 5 April 2011, accessed March 2012
  35. British American Tobacco, British American Tobacco established stand-alone company, Nicoventures Limited, News release, BAT website, 5 April 2011, accessed November 2019
  36. V. Allen, B. Spencer, NHS plan to prescribe e-cigarettes goes up in smoke after the only device licences for medical use if aced, The Daily Mail, 5 February 2018, accessed November 2019
  37. S. Manning, British American Tobacco enters electronic cigarette market in Britain with the ‘Vype’, Independent, 29 July 2013, accessed November 2019
  38. A. Ralph, Tobacco Giant buys electronic cigarette maker. The Times, 20 December 2012, accessed June 2013
  39. Manchester Evening News, CN Creative sold to British American Tobacco, Manchester Evening News, 19 December 2012, accessed February 2020
  40. British American Tobacco, Annual Report and Form 20-F 2019, accessed July 2021
  41. British American Tobacco, Half-year Report for the six months to June 2019: Presentation Transcript, BAT website, 01 August 2019, accessed August 2019
  42. abJ. Bowles, T. Marroco, Sell Side Presentation, British American Tobacco, 12 September 2019, accessed November 2019
  43. British American Tobacco, 2018 Sustainability Report, BAT website, March 2019, accessed February 2020
  44. abcdefN. Durante, Analyst Briefing, British American Tobacco, 16 October 2018, accessed November 2019
  45. British American Tobacco New Zealand, Vype ePen 3 launched in New Zealand, News Release, BAT NZ website, undated, accessed November 2019
  46. British American Tobacco,, archived 1 January 2021, accessed July 2021
  47. abBAT launches, Business Wire, 3 December 2020, archived 12 January 2021, accessed July 2021
  48. British American Tobacco, Why Vape Explained/Marketing Code, undated, accessed July 2021
  49. 75Imperial Tobacco Canada (BAT), Vaping: Let’s Clear the Smoke, press release, 14 February 2022, accessed February 2022
  50. British American Tobacco Germany, BAT launches the pioneering tobacco-free veo range, press release, 14 September 2023
  51. Heated Tobacco Products, Tobacco Insider, 9 October 2023, accessed October 2023
  52. E. Rumney, Big Tobacco turns to rooibos tea to counter upcoming ban, Reuters, 16 October 2023, accessed October 2023
  53. Italian watchdog fines BAT and Amazon over misleading advertising, Reuters, 14 February 2024, accessed February 2024
  54. British American Tobacco, BAT and PMI Announce Global Patent Settlement, press release, 2 February 2024, accessed February 2024
  55. Press Association, British American Tobacco looking into cannabis vape flavours, Daily Mail: This is Money, 10 February 2020, accessed November 2020
  56. British American Tobacco, BAT launches first CBD vaping product, BAT website, undated, archived 12 January 2021, accessed January 2021
  57. British American Tobacco, The role of e-cigarettes in tobacco harm reduction, BAT website, page archived 28 March 2014, accessed September 2019
  58. British American Tobacco, E-cigarettes and other Next Generation Products, BAT website, undated, accessed September 2019
  59. British American Tobacco, Vapour Products, BAT website, page archived 20 March 2018, accessed August 2019
  60. British American Tobacco, Understanding the relative risks of our products, website, undated, archived 2 March 2021, accessed July 2021
  61. abBritish American Tobacco, Half-year Report for the six months to June 2019, 01 August 2019, accessed August 2019
  62. British American Tobacco, Reduced-risk products, website, undated, archived 3 June 2021, accessed July 2021
  63. British American Tobacco, Understanding the comparative risks of our products, website, undated, accessed July 2021
  64. abcdefghiP. Lageweg, “Step-Changing New Categories: A very significant growth opportunity”, British American Tobacco Investor Day Presentation, BAT website, 14 March 2019, accessed February 2020
  65. abBritish American Tobacco, Accelerating a Better Tomorrow, Annual Report, 2021, Available from the
  66. R. Davies, British American Tobacco cuts 2,300 jobs in shift towards vaping, The Guardian, 12 September 2019, accessed November 2019
  67. J. Faurschou, Up in smoke: Tobacco companies and the future of vaping, Investors Chronicle, 3 October 2019, accessed November 2019
  68. British American Tobacco, British American Tobacco to focus on three global new category brands to further accelerate their growth, News Release, BAT website, 28 November 2019, accessed December 2019
  69. British American Tobacco, 2020 preliminary results, press release, 17 February 2021
  70. abBritish American Tobacco, Deutsche Bank Global Consumer Conference, Presentation transcript, 9 June 2021, accessed August 2021
  71. British American Tobacco, Creating a Better Tomorrow, website homepage, undated, accessed March 2020
  72. abBritish American Tobacco, Our purpose and strategy, undated, archived 11 April 2020, accessed April 2024
  73. abPhysicians for a Smoke-Free Canada, BAT targets Canadian vaping market with higher nicotine and more flavours, blog, 1 February 2021, accessed August 2021. Cites evidence from Statistics Canada, and UK Office for National Statistics
  74. abPhysicians for a Smoke-Free Canada, BAT Marketing of Vuse/Vype, January 2021